Fig. 4: Knockdown of STING reverses the anti-tumor effect of ARIH1- enhanced PD-L1 blockade therapy.

a, b Representative tumor growth curves and final tumor weights of tumors (including CTRL, Arih1^-WT-OE, and Arih1^-WT-OE&Sting-KD) in female BALB/c mice (6–8 week old) with the indicated treatments after subcutaneous injection of 5 × 10⁵ 4T1 cells. n = 6 mice/group. Data represent means ± SEM. a ^****P < 0.0001. b ^*P < 0.05 (P = 0.0492), ^**P < 0.01 (P = 0.0027), ^***P < 0.001 (P = 0.0002), ns, not significant. c, d Representative figures and summary of frequency of tumor infiltrating CD8⁺ T cells and GzmB⁺CD8⁺ T cells of the mice as in a. n = 6, 6, 4, 6 mice/group. Data represent means ± SEM. c ^**P < 0.01 (P = 0.0083), ^***P < 0.001, ns, not significant. d ^*P < 0.05 (P = 0.0341), ^**P < 0.01 (P = 0.0022), ^***P < 0.001 (P = 0.0010), ns, not significant. e, f CD8 and GzmB IHC staining were performed in tumors of the mice as in a. The percent of each expression pattern was quantified f. Scale bar, 60 μm. n = 6, 6, 4, 6 mice/group. Data represent means ± SEM, ^****P < 0.0001, ns, not significant. g Immunoblot analysis of pSTING-S365, STING, and ARIH1 in indicated tumor lysates for the experiment described in a. h qRT-PCR measurement of ISGs for the tumors of the mice as in a. n = 6, 6, 4, 6 mice/group. Data represent means ± SEM, ^****P < 0.0001, ns, not significant. For a data, Two-way ANOVA test. For b–d, f, and h data, One-way ANOVA test. Source data are provided as a Source Data file.